Levels of Inflammation in Middle East People With Cardiovascular Disease With/Without Kidney Disease
NCT ID: NCT06655493
Last Updated: 2025-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
756 participants
OBSERVATIONAL
2024-11-22
2025-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to assess the number of people with high levels of systemic inflammation among Middle East people with cardiovascular with/without kidney disease. Systemic inflammation means that it occurs throughout the body.
Participation in this study only requires a single visit at the clinic/hospital/medical institution. Participants will continue their normal care and will not get any treatment as part of this study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
NCT06122961
Cardiovascular Patients With no Standard Modifiable Risk Factors
NCT06199869
Inflammation as a Predictor in Cardioversion of Atrial Fibrillation
NCT00590525
Inflammation Markers Over Time in Cardiovascular Disease
NCT00005692
Genetic and Immunity in Heart Failure
NCT06758128
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ASCVD with CKD
Study participants diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD) with Chronic Kidney Disease (CKD)
No treatment given
Participants will continue their normal care and will not get any treatment as part of this study.
HFpEF or HFmrEF
Study participants diagnosed with Heart Failure (HF) with preserved ejection fraction (HFpEF) or HF with mildly reduced ejection fraction (HFmrEF)
No treatment given
Participants will continue their normal care and will not get any treatment as part of this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No treatment given
Participants will continue their normal care and will not get any treatment as part of this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female, age above or equal to 18 years at the time of signing informed consent.
3. Diagnosed with ASCVD+CKD and/or HF (pEF or mrEF)
Exclusion Criteria
2. Current participation (i.e., signed informed consent) in any other interventional clinical study.
3. Any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization).
4. Clinical evidence, or suspicion of, active infection within the last 60 days.
5. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Transparency (dept. 2834)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Almoosa Specialist Hospital
Al Ahsa, , Saudi Arabia
King Fahad Armed Forces, Jeddah
Jeddah, , Saudi Arabia
King Faisal Specialist Hospital & Research Centre, Jeddah
Jeddah, , Saudi Arabia
Dr. Sulaiman Al Habib Medical Group- Olaya
Riyadh, , Saudi Arabia
King Khaled University Hospital,King Saud Univ. Med. City
Riyadh, , Saudi Arabia
Dallah Hospital_Riyadh
Riyadh, , Saudi Arabia
King Faisal Specialist Hospital & Research Centre, Riyadh
Riyadh, , Saudi Arabia
SMC, Riyadh
Riyadh, , Saudi Arabia
King Fahad Medical City
Riyadh, , Saudi Arabia
King Salman North Western Armed Force Hospital (NWAFH)
Tabuk, , Saudi Arabia
Cleveland Clinic Abu Dhabi
Abu Dhabhi, , United Arab Emirates
Tawam Hospital (SEHA)
Abu Dhabhi, , United Arab Emirates
Mediclinic Abu Dhabi
Abu Dhabhi, , United Arab Emirates
Imperial college, Abu Dhabi
Abu Dhabhi, , United Arab Emirates
Fujairah Hospital
Al Fujairah City, , United Arab Emirates
Sheikh Khalifa Hospital Fujairah
Al Fujairah City, , United Arab Emirates
Tadwai hospital
Dubai, , United Arab Emirates
Rashid Hospital
Dubai, , United Arab Emirates
Dubai Hospital
Dubai, , United Arab Emirates
Al Qassimi Hospital, Sharjah
Sharjah city, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1303-1767
Identifier Type: OTHER
Identifier Source: secondary_id
DAS-8043
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.